Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026)

Neumora Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $119000.0 for Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $119000.0 (changed N/A YoY), while the FY2025 annual figure was $193000.0, changed N/A from the prior year.
• Operating Leases was $119000.0 for Q1 2026 at Neumora Therapeutics, down from $193000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.1 million in Q4 2022 to a low of $119000.0 in Q1 2026.
• Historically, Operating Leases has averaged $1.4 million across 5 years, with a median of $638500.0 in 2024.
• Biggest YoY gain for Operating Leases was 63.47% in 2023; the steepest drop was 63.47% in 2023.
• A 5-year view of Operating Leases shows it stood at $5.1 million in 2022, then tumbled by 63.47% to $1.9 million in 2023, then plunged by 49.38% to $938000.0 in 2024, then tumbled by 79.42% to $193000.0 in 2025, then slumped by 38.34% to $119000.0 in 2026.
• The last three Operating Leases figures came in at $119000.0 (Q1 2026), $193000.0 (Q4 2025), and $267000.0 (Q3 2025), per Business Quant data.